138 related articles for article (PubMed ID: 11750320)
1. TNF:TNF-R T-Cell costimulatory pathways in transplantation.
Yamada A; Salama AD; Najafian N; Auchincloss H; Sayegh MH
Transplant Proc; 2001; 33(7-8):3070-1. PubMed ID: 11750320
[No Abstract] [Full Text] [Related]
2. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
Brook MO; Jones ND; Wood KJ
Transplantation; 2005 Jul; 80(2):253-4. PubMed ID: 16041271
[No Abstract] [Full Text] [Related]
3. Update on CD40 and CD154 blockade in transplant models.
Zhang T; Pierson RN; Azimzadeh AM
Immunotherapy; 2015; 7(8):899-911. PubMed ID: 26268734
[TBL] [Abstract][Full Text] [Related]
4. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
[TBL] [Abstract][Full Text] [Related]
5. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway.
Niimi M; Shirasugi N; Ikeda Y; Kan S; Takami H; Hamano K
Transplantation; 2001 Nov; 72(9):1556-62. PubMed ID: 11707745
[TBL] [Abstract][Full Text] [Related]
6. CD40 and its ligand in autoimmunity.
Noelle RJ; Mackey M; Foy T; Buhlmann J; Burns C
Ann N Y Acad Sci; 1997 Apr; 815():384-91. PubMed ID: 9186684
[No Abstract] [Full Text] [Related]
7. Recent advances in tumor necrosis factor and CD40 signaling.
Tewari M; Dixit VM
Curr Opin Genet Dev; 1996 Feb; 6(1):39-44. PubMed ID: 8791485
[TBL] [Abstract][Full Text] [Related]
8. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses.
Ye Q; Wang L; Wells AD; Tao R; Han R; Davidson A; Scott ML; Hancock WW
Eur J Immunol; 2004 Oct; 34(10):2750-9. PubMed ID: 15368291
[TBL] [Abstract][Full Text] [Related]
9. Contribution of CD40-CD154-mediated costimulation to an alloresponse in vivo.
Förster E; Krenger W; Joergensen J; Hof R; Geha RS; Holländer GA
Transplantation; 1999 May; 67(9):1284-7. PubMed ID: 10342324
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.
Fiumara P; Younes A
Br J Haematol; 2001 May; 113(2):265-74. PubMed ID: 11380390
[No Abstract] [Full Text] [Related]
11. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
[TBL] [Abstract][Full Text] [Related]
12. Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival.
Chang AC; Blum MG; Blair KS; Scott MA; Brock JE; Thomas DW; Burkly LC; Miller GG; Pierson RN
Transplant Proc; 1999; 31(1-2):95. PubMed ID: 10083025
[No Abstract] [Full Text] [Related]
13. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
14. CD40-CD40 ligand: a multifunctional receptor-ligand pair.
Van Kooten C; Banchereau J
Adv Immunol; 1996; 61():1-77. PubMed ID: 8834494
[No Abstract] [Full Text] [Related]
15. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
[TBL] [Abstract][Full Text] [Related]
16. Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway.
van Maurik A; Wood KJ; Jones ND
Transplantation; 2002 Sep; 74(5):740-3. PubMed ID: 12352896
[TBL] [Abstract][Full Text] [Related]
17. Analysis of costimulation by 4-1BBL, CD40L, and B7 in graft rejection by gene expression profiles.
DeFina R; Christopher K; He H; Mandelbrot D; Gu Y; Finn P; Perkins DL
J Mol Med (Berl); 2003 Oct; 81(10):655-63. PubMed ID: 12937898
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
19. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.
Larsen CP; Elwood ET; Alexander DZ; Ritchie SC; Hendrix R; Tucker-Burden C; Cho HR; Aruffo A; Hollenbaugh D; Linsley PS; Winn KJ; Pearson TC
Nature; 1996 May; 381(6581):434-8. PubMed ID: 8632801
[TBL] [Abstract][Full Text] [Related]
20. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria.
Carlsen HS; Yamanaka T; Scott H; Rugtveit J; Brandtzaeg P
Inflamm Bowel Dis; 2006 Nov; 12(11):1013-24. PubMed ID: 17075342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
